Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can digestive enzymes help pancreatic cancer patients keep weight on?

NCT ID NCT05642962

Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether taking pancreatic enzymes (Pertzye) with meals can help people with metastatic pancreatic cancer maintain their body weight during chemotherapy. The trial includes 17 participants who are starting a standard chemo regimen called FOLFIRINOX. Researchers will measure changes in body mass index (BMI) over 4 months and compare two different doses of the enzyme supplement.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pancreatic enzymes (Pertzye, also known as pancrelipase)
What this could lead to
If it works, this could help patients with metastatic pancreatic cancer maintain their weight and nutritional status during chemotherapy.
What could go wrong
This is a very early, small study (17 people) testing a supportive therapy, not a cancer treatment. It may not show meaningful benefit, and results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

17 people

The number who actually took part.

Started

Nov 2022

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histopathologic or cytologic diagnosis of pancreatic adenocarcinoma, or adenosquamous cancer, or any non-neuroendocrine primary pancreas variant, including acinar cancer. * De novo or recurrent diagnosis of previously untreated stage IV PDAC with intent to receive FOLFIRINOX/mFOLFIRINOX. * ECOG 0-2. * No use of pancreatic enzyme replacement therapy within prior 2 weeks. * Patients with biliary obstruction are eligible provided biliary stenting has or will occur before treatment with FOLFIRINOX. * Ability to understand and the willingness to sign an informed consent document. * Ability to swallow capsules. * Age ≥18 years. * Anticipated life expectancy of at least 6 months. Exclusion Criteria: * Chronic illness associated with malabsorption (celiac disease, cystic fibrosis, chronic pancreatitis, Crohn's disease). * Fibrosing colonopathy. * Prior history of surgical resection of the pancreas or gastric bypass. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to Pancrelipase. * Patients cannot receive radiation, IRE, or other localized therapy directed to the pancreas while on study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic pancreatic adenocarcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm metastatic carcinoma pancreatic adenocarcinoma pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic pancreatic adenocarcinoma Metastatic pancreatic cancer Metastatic pancreatic carcinoma Metastatic pancreatic ductal adenocarcinoma Pancreatic cancer Pancreatic cancer metastatic Pancreatic cancer non-resectable Pancreatic cancer stage IV Pancreatic carcinoma Pancreatic carcinoma metastatic Pancreatic carcinoma non-resectable PDAC Pdac - pancreatic ductal adenocarcinoma

Contacts and locations

Locations

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)

    Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.